Trend Breakdown

The Evidence

Do NAD+ boosters actually do anything?

NAD+ genuinely declines with age, and NR or NMN supplements reliably raise it back up within weeks in human trials. Six studies later, though, none has shown that a higher NAD+ reading translates into better blood sugar, body composition or a longer life.

Published 29 Jul 2026 · 4 min read · 6 sources

Skip to the verdict ↓

Trend Science
Breakdown

Evidence-graded series

02What's being claimed

Advocates argue that since NAD+ measurably declines with age and drives hundreds of metabolic reactions, restoring it with over-the-counter NR or NMN should reverse cellular ageing and restore a more youthful metabolism. The idea traces directly back to rodent longevity research and a Harvard scientist's own daily supplement routine.

The underlying chemistry is not in dispute. Rajman et al.'s 2018 review in Cell Metabolism confirmed NAD+ concentrations fall with age across species and tissues, and that restoring them with NAD+ precursors improves healthspan markers in animal models ¹. Human trials back up half of that story: Conze et al. found NR supplementation doubled NAD+ metabolome markers in humans within eight weeks, safely and reproducibly ³.

That scientific premise met a famous champion. David Sinclair, whose Harvard lab had run the foundational rodent studies, publicised his own daily NMN regimen in his bestselling book and on the podcast circuit, turning a lab biomarker into a consumer routine. From 2022 onward, TikTok longevity content and a wave of direct-to-consumer NMN and NR brands pushed the trend further, treating a rising blood NAD+ number as proof of measurable anti-ageing progress, even though that proof was never tested in the trials that followed.

Origin

Sinclair Lab, Harvard

Sinclair lab rodent studies in the mid-2010s showed NAD+ precursors reversing age-related metabolic decline.

→

Vector

Sinclair's Lifespan Book

His bestselling book and podcast appearances publicised his own daily NMN regimen to a mass audience.

→

Spike

TikTok Longevity Influencers

TikTok and Instagram longevity content, plus direct-to-consumer NMN and NR brands, drove a search surge from 2022.

"People say NMN turned back their biological clock: a spike in energy and mental clarity within days, and proof that a rising NAD+ number on a lab test is the objective marker sceptics keep demanding but never mention."

- Representative of the claim as it circulates online

03The evidence verdict

HiPerformance Culture The Evidence · Trend Breakdown

Verdict

NR and NMN reliably raise blood NAD+, but no human trial has shown a matching health benefit.

This trend lands here

Evidence for the claim: 26/100 (Low) 6 sources cited · 1 mechanism review, 2 RCTs, 2 meta-analyses, 1 systematic review · 2018-2026 · how we grade ↓

Every line below is graded by the strength of the evidence behind it.

Gold: strongest available evidence
Silver: solid, not decisive
Bronze: preliminary or indirect

how we grade ↓

✓

What holds up

✓

NAD+ falls measurably with age, and NR or NMN reliably raises blood NAD+ markers in humans within weeks ¹³.

GoldSupporting study: Rajman 2018 Supporting study: Conze 2019

✓

NR and NMN are well tolerated at doses up to 2,000mg/day (NR) and 1,200mg/day (NMN) for 12 weeks, with only mild, transient digestive complaints ³².

GoldSupporting study: Conze 2019 Supporting study: Dollerup 2018

✓

NMN modestly lowers resting diastolic blood pressure in adults aged 60 and over, with a smaller effect on systolic pressure ⁵.

SilverSupporting study: Zhang 2026

✓

A pooled analysis of 10 trials (437 patients) found modest improvements in some physical performance measures with NMN, though trial quality was limited ⁴.

BronzeSupporting study: Wen 2024

What doesn't

A meta-analysis of 8 RCTs (342 adults) found no significant benefit of NMN on fasting glucose, insulin, HbA1c, insulin resistance or lipid profile ⁶.

GoldSupporting study: Chen 2024

A 12-week RCT in obese, insulin-resistant men found NR doubled NAD+ markers yet produced no improvement in insulin sensitivity, body composition or weight ².

GoldSupporting study: Dollerup 2018

No published human trial has tested whether raising NAD+ via NR or NMN extends lifespan or slows biological ageing; all human evidence runs 12 weeks or less ¹.

GoldSupporting study: Rajman 2018

04So what do you actually do

If you want to try NAD+ boosters, treat them as a biomarker experiment, not an anti-ageing protocol.

Raising NAD+ is real and safe at studied doses; a proven metabolic or longevity benefit is not.

01Treat NR or NMN as a low-risk supplement that raises a blood biomarker, not a validated anti-ageing treatment.

02Stick to studied dose ranges: up to 2,000mg/day for NR and up to 1,200mg/day for NMN, for periods of 12 weeks or less.

03Do not expect measurable changes in blood glucose, insulin sensitivity or weight; the largest trials found none.

04If you are over 60 and focused on blood pressure, note the modest diastolic effect seen in one meta-analysis, not a cure.

05Prioritise exercise, sleep and diet quality first, since these have the stronger evidence base for metabolic and healthspan benefit.

05The studies

Tier inputs Design quality Measurement precision Causal clarity Replication value

GoldThe strongest evidence available for the specific line it supports: typically systematic reviews, meta-analyses, or randomised trials, or definitive mechanistic work where the line is a mechanistic claim.

SilverSolid but not decisive support: controlled or observational studies, or direct evidence that is small or not yet replicated.

BronzePreliminary or indirect signals; suggestive, never sufficient on their own.

A per-source tier is displayed only when all four axis scores and the weights and thresholds that compute the tier are recorded. Sources without those inputs remain unscored; no tier is inferred from a design label, sample-size phrase, or existing editorial chip. Every source still discloses its design and a resolvable DOI.

Narrative review of in vivo evidence

Rajman et al. Cell Metabolism · 2018

Rajman et al. found NAD+ declines with age across species and tissues, and pharmacological restoration with NAD+ precursors improves healthspan markers in animal models, though the review notes human outcome data lag far behind the preclinical case.

doi:10.1016/j.cmet.2018.02.011 Verify ↗

0% change in insulin sensitivity vs placebo

RCT, 12 weeks, n=40 obese men

Dollerup et al. The American Journal of Clinical Nutrition · 2018

Dollerup et al. gave 40 obese, insulin-resistant men NR for 12 weeks and found it safe, doubling NAD+ metabolome markers, but insulin sensitivity, body composition and weight were unchanged versus placebo, with only a small secondary drop in hepatic lipid content.

doi:10.1093/ajcn/nqy132 Verify ↗

Contested : Preclinical rodent studies predicted a metabolic benefit that did not replicate in this human trial.

2x increase in NAD+ metabolome at highest dose

RCT, 8 weeks, n=140 healthy overweight adults

Conze et al. Scientific Reports · 2019

Conze et al. gave 140 healthy overweight adults NR for eight weeks and found it well tolerated, with no serious adverse events, producing dose-dependent increases in blood NAD+ metabolome markers that confirmed the biomarker effect held at scale.

doi:10.1038/s41598-019-46120-z Verify ↗

10 RCTs pooled (437 patients)

Systematic review of RCTs, n=437 across 10 trials

Wen et al. Cureus · 2024

Wen et al. pooled 10 RCTs covering 437 patients and found modest improvements in some physical performance parameters with NMN doses of 150 to 1,200mg per day, but flagged small sample sizes and inconsistent outcome measures across the included trials.

doi:10.7759/cureus.65961 Verify ↗

Contested : Effect sizes were small and heterogeneous across included trials.

60+ age group showing the clearest blood-pressure signal

Systematic review and meta-analysis of RCTs

Zhang et al. Nutrients · 2026

Zhang et al.'s meta-analysis of NMN trials found supplementation was associated with a modest reduction in resting diastolic blood pressure, an effect concentrated in adults aged 60 and older, with a smaller signal on systolic blood pressure.

doi:10.3390/nu18060890 Verify ↗

0 metabolic outcomes significantly improved of 5 measured

Meta-analysis, 8 RCTs, n=342 middle-aged/older adults

Chen et al. Current Diabetes Reports · 2024

Chen et al. pooled eight RCTs covering 342 middle-aged and older adults and found no significant benefit of NMN supplementation on fasting glucose, fasting insulin, HbA1c, insulin resistance or lipid profile in this mostly healthy, non-diabetic population.

doi:10.1007/s11892-024-01557-z Verify ↗

06The verdict triad

Claim

The biomarker claim is real

NAD+ genuinely declines with age, and advocates argue that restoring it with NR or NMN reverses cellular ageing and restores a more youthful metabolism, a claim inherited directly from rodent studies and popularised by a prominent Harvard longevity researcher.

Consequence

No proven metabolic benefit

Raising NAD+ with NR or NMN does not reliably improve glucose control, insulin sensitivity, or lipid profile in controlled human trials, and no human trial has tested whether it extends lifespan.

Lever

Invest in proven levers instead

Direct effort toward levers with a proven metabolic and healthspan benefit, such as regular exercise, consistent sleep, and diet quality, rather than substituting an unproven supplement for the habits that actually move the needle.

07The protocol

08What to do next

What to do next

Curious whether your longevity stack needs more than a NAD+ supplement?

The HPC Metabolic Health Self-Assessment checks whether your daily habits already cover the ground NR and NMN have not yet proven they can.

Take the metabolic health assessment

09Share & references

Update log

29 Jul 2026First published. 6 sources reviewed; verdict: Low confidence that NAD+ boosters (NR/NMN) reliably raise blood NAD+ but lack a proven metabolic or longevity benefit.

20 Aug 2026Machine layer added: structured claim data with an authored veracity verdict, accessible meter with stated evidence position, grading disclosure, and related links and calls to action wired to live destinations.

Next reviewDue by February 2027, or earlier if a new controlled trial or systematic review lands.

Bibliography · every source, resolvable

01Rajman, L., Chwalek, K. & Sinclair, D.A. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism, 27(3), 529-547. doi:10.1016/j.cmet.2018.02.011 Verify ↗

02Dollerup, O.L., Christensen, B., Svart, M., Schmidt, M.S., Sulek, K., Ringgaard, S., Stødkilde-Jørgensen, H., Møller, N., Brenner, C., Treebak, J.T. & Jessen, N. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. The American Journal of Clinical Nutrition, 108(2), 343-353. doi:10.1093/ajcn/nqy132 Verify ↗

03Conze, D., Brenner, C. & Kruger, C.L. (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Scientific Reports, 9(1). doi:10.1038/s41598-019-46120-z Verify ↗

04Wen, J., Syed, B., Kim, S., Shehabat, M., Ansari, U., Razick, D.I., Akhtar, M. & Pai, D. (2024). Improved Physical Performance Parameters in Patients Taking Nicotinamide Mononucleotide (NMN): A Systematic Review of Randomized Control Trials. Cureus. doi:10.7759/cureus.65961 Verify ↗

05Zhang, M., Chen, Y., Jiang, N., Zeng, J., Zhang, J., Wu, C., Liu, Y., Nie, Z., Yang, J. & Han, S. (2026). Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 18(6), 890. doi:10.3390/nu18060890 Verify ↗

06Chen, F., Zhou, D., Kong, A.P., Yim, N.T., Dai, S., Chen, Y.N. & Hui, L.L. (2024). Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials. Current Diabetes Reports, 25(1). doi:10.1007/s11892-024-01557-z Verify ↗